Zai Lab Limited (ZLAB)Healthcare | Biotechnology | Pudong, China | NasdaqGM
24.19 USD
+0.69
(2.936%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 23.80 -0.39 (-0.390%) ⇩ (April 17, 2026, 5:12 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 19, 2026, 12:50 a.m. EDT
Zai Lab is in a high-conviction short-term momentum phase driven by the recent 35% rally (from March highs), with a clear floor established around $17.50 where deep OTM puts accumulate. The 5-star short-term target is not the analyst's $37 yet, but rather the technical resistance near $25-$28 followed by a rapid flush or breakout, as capital is aggressively buying protections at $20-22 while funding upside calls at nearby strikes. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.117609 |
| AutoETS | 0.117704 |
| AutoARIMA | 0.119505 |
| MSTL | 0.119681 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 3.37 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.714 |
| Excess Kurtosis | 0.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 31.343 |
| Revenue per Share | 4.201 |
| Market Cap | 2,731,968,256 |
| Forward P/E | -17.33 |
| Beta | 0.86 |
| Profit Margins | -38.15% |
| Website | https://www.zailaboratory.com |
As of April 19, 2026, 12:50 a.m. EDT: Near-term options (April 17) show aggressive positioning: 101 contracts bought at the 20 strike and 162 OTM puts at the 15 strike, indicating a risk approval but slight downside protection cap. However, the massive disparity in volume/OTM vs ITM (high OTM OI percentage) suggests speculative momentum plays rather than directional bets. The call skew favoring strikes 20-25 aligns with the recent 15% price surge from 17.85 to 24.19. Shorter-dated puts (April 17) see high volume, but the lack of ITM puts suggests sellers aren't pricing in a crash, but rather volatility around the 20 price floor.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.18579602 |
| Address1 | Building B |
| Address2 | 899 Halei Road |
| All Time High | 193.54 |
| All Time Low | 13.48 |
| Ask | 24.66 |
| Ask Size | 8 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 883,080 |
| Average Daily Volume3 Month | 746,586 |
| Average Volume | 746,586 |
| Average Volume10Days | 883,080 |
| Beta | 0.857 |
| Bid | 23.96 |
| Bid Size | 8 |
| Book Value | 6.467 |
| City | Pudong |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | China |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 24.19 |
| Current Ratio | 2.449 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 24.6699 |
| Day Low | 23.74 |
| Debt To Equity | 31.343 |
| Display Name | Zai Lab |
| Earnings Call Timestamp End | 1,772,110,800 |
| Earnings Call Timestamp Start | 1,772,110,800 |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -214,424,000 |
| Ebitda Margins | -0.46598 |
| Enterprise To Ebitda | -122.648 |
| Enterprise To Revenue | 57.152 |
| Enterprise Value | 26,298,681,344 |
| Eps Current Year | -1.92148 |
| Eps Forward | -1.39619 |
| Eps Trailing Twelve Months | -1.6 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.5224 |
| Fifty Day Average Change | 4.6676006 |
| Fifty Day Average Change Percent | 0.23908949 |
| Fifty Two Week Change Percent | -18.579601 |
| Fifty Two Week High | 44.34 |
| Fifty Two Week High Change | -20.15 |
| Fifty Two Week High Change Percent | -0.45444292 |
| Fifty Two Week Low | 15.96 |
| Fifty Two Week Low Change | 8.2300005 |
| Fifty Two Week Low Change Percent | 0.5156642 |
| Fifty Two Week Range | 15.96 - 44.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,914,200,000 |
| Float Shares | 960,339,486 |
| Forward Eps | -1.39619 |
| Forward P E | -17.325722 |
| Free Cashflow | -92,507,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,784 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.10468 |
| Gross Profits | 48,171,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.018960001 |
| Held Percent Institutions | 0.34655997 |
| Implied Shares Outstanding | 112,937,910 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Turning Point Therapeutics, Inc. to develop and commercialize products containing repotrectinib; Entasis Therapeutics Holdings Inc. to develop and commercialize Durlobactam with Sulbactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for Tisotumab Vedotin; and strategic collaboration with Boehringer Ingelheim GmbH for the development of DLL3-targeting combination therapies for the treatment of small cell lung cancer and other neuroendocrine carcinomas. The company was incorporated in 2013 and is based in Pudong, China. |
| Long Name | Zai Lab Limited |
| Market | us_market |
| Market Cap | 2,731,968,256 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_271123063 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -175,536,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,631,212,785 |
| Number Of Analyst Opinions | 12 |
| Open | 23.91 |
| Operating Cashflow | -150,788,992 |
| Operating Margins | -0.54395 |
| Payout Ratio | 0.0 |
| Phone | 86 21 6163 2588 |
| Post Market Change | -0.3900013 |
| Post Market Change Percent | -1.6122417 |
| Post Market Price | 23.8 |
| Post Market Time | 1,776,460,347 |
| Previous Close | 23.5 |
| Price Eps Current Year | -12.589254 |
| Price Hint | 2 |
| Price To Book | 3.7405288 |
| Price To Sales Trailing12 Months | 5.937048 |
| Profit Margins | -0.38147 |
| Quick Ratio | 1.941 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.690001 |
| Regular Market Change Percent | 2.93617 |
| Regular Market Day High | 24.6699 |
| Regular Market Day Low | 23.74 |
| Regular Market Day Range | 23.74 - 24.6699 |
| Regular Market Open | 23.91 |
| Regular Market Previous Close | 23.5 |
| Regular Market Price | 24.19 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,451,689 |
| Return On Assets | -0.12162 |
| Return On Equity | -0.22557 |
| Revenue Growth | 0.17 |
| Revenue Per Share | 4.201 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 112,669,482 |
| Shares Percent Shares Out | 0.0473 |
| Shares Short | 5,332,652 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,800,411 |
| Short Name | Zai Lab Limited |
| Short Percent Of Float | 0.053600002 |
| Short Ratio | 7.15 |
| Source Interval | 15 |
| Symbol | ZLAB |
| Target High Price | 55.0 |
| Target Low Price | 21.8 |
| Target Mean Price | 37.31083 |
| Target Median Price | 34.27 |
| Total Cash | 689,572,992 |
| Total Cash Per Share | 0.623 |
| Total Debt | 224,259,008 |
| Total Revenue | 460,156,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.6 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.28205 |
| Two Hundred Day Average Change | -1.0920486 |
| Two Hundred Day Average Change Percent | -0.043194626 |
| Type Disp | Equity |
| Volume | 1,451,689 |
| Website | https://www.zailaboratory.com |
| Zip | 201,203 |